Cardiology overview heart failure: Difference between revisions
Jump to navigation
Jump to search
| Line 19: | Line 19: | ||
===Enoxaparin and Antiocagulation=== | ===Enoxaparin and Antiocagulation=== | ||
* While hospitalized, patients with CHF should receive [[DVT prophylaxis]] | * While hospitalized, patients with CHF should receive [[DVT prophylaxis]] | ||
===Drugs to Avoid in CHF=== | |||
* [[Dronedarone]] | |||
* [[Sotalol]] (has a negative inotropic effect) | |||
==Invasive Monitoring== | ==Invasive Monitoring== | ||
Revision as of 15:59, 31 October 2011
|
Cardiology Overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Pharmacotherapy
Angiotensin Converting Enzyme (ACE) Inhibition
- Improve LV remodeling following ST elevation MI
- Even in patients who are asymptomatic with LV dysfunction, this class improves the odds of developing symptoms and survival.
Lasix
- Higher lasix doses are associated with higher mortality, likely as a surrogate of disease severity rather than part of a causal pathway.
Beta Blockers
Lopressor should be used instead of atenolol in the patient with CHF
Metformin
Enoxaparin and Antiocagulation
- While hospitalized, patients with CHF should receive DVT prophylaxis
Drugs to Avoid in CHF
- Dronedarone
- Sotalol (has a negative inotropic effect)
Invasive Monitoring
- Based upon the results of the ESCAPE trial, there is no benefit in clinical outcomes with the use of a pulmonary artery line in patients with decompensated CHF.
Obstructive Sleep Apnea in the Patient with CHF
- Central sleep apnea in the patient with CHF is due to the compensatory respiratory alkalosis that is present in the patient with CHF and tachypnea